Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: VS-6063 Clear all
Terminated Phase 2 Interventional

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

NCT01870609
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
defactinib (VS-6063), Placebo
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
San Francisco, California • Weston, Florida • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Nov 12, 2026, 5:22 AM EST
Terminated Phase 1 Interventional

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

NCT02943317
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Part A - VS-6063, Part A - Avelumab
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Sarasota, Florida • Boston, Massachusetts • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Nov 12, 2026, 5:22 AM EST
Recruiting Phase 2 Interventional

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

NCT06495125
View directory record Official record
Conditions
Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Avutometinib, Biopsy, Biospecimen Collection, Computed Tomography, Defactinib, Nivolumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Active, not recruiting Early Phase 1 Interventional

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

NCT05798507
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
Avutometinib, Biospecimen Collection, Defactinib
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 12, 2026, 5:22 AM EST
Completed Phase 2 Interventional Results available

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

NCT03727880
View directory record Official record
Conditions
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Interventions
Pembrolizumab, Defactinib
Drug
Lead sponsor
Lei Zheng
Other
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Recruiting Phase 1 Interventional

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

NCT07318324
View directory record Official record
Conditions
Phase IB, Avutometinib, RAS Pathway, Endometrial
Interventions
Avutometinib, defactinib, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Active, not recruiting Phase 2 Interventional

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

NCT04331041
View directory record Official record
Conditions
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
Interventions
Adaptive stereotactic body radiation therapy, Defactinib, Tumor biopsy, Research blood draw
Device · Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Recruiting Phase 2 Interventional

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

NCT06369259
View directory record Official record
Conditions
Advanced Colorectal Cancer
Interventions
Defactinib, Cetuximab, Avutometinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

NCT07020221
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Interventions
VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Terminated Phase 1Phase 2 Interventional Results available

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

NCT03287271
View directory record Official record
Conditions
Ovarian Cancer
Interventions
VS-6063, Paclitaxel, Carboplatin
Drug
Lead sponsor
Michael McHale
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810
View directory record Official record
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Interventions
avutometinib and sotorasib, avutometinib and sotorasib and defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Boulder, Colorado • Washington D.C., District of Columbia • Arlington Heights, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Recruiting Phase 1Phase 2 Interventional

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

NCT06194929
View directory record Official record
Conditions
Cutaneous Melanoma, Brain Metastases
Interventions
Defactinib, Avutometinib, Encorafenib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Iowa City, Iowa • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Nov 12, 2026, 5:22 AM EST
Completed Phase 1 Interventional

A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies

NCT00787033
View directory record Official record
Conditions
Cancer
Interventions
PF-04554878
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Nov 12, 2026, 5:22 AM EST
Completed Phase 2 Interventional

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

NCT04620330
View directory record Official record
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Interventions
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
28
States / cities
Duarte, California • Aurora, Colorado • Lone Tree, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Nov 12, 2026, 5:22 AM EST
Completed Phase 2 Interventional

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

NCT01951690
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer
Interventions
defactinib (VS-6063)
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Denver, Colorado • Atlanta, Georgia • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Nov 12, 2026, 5:22 AM EST
Recruiting Phase 2 Interventional

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

NCT05512208
View directory record Official record
Conditions
Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer, Solid Tumor
Interventions
Avutometinib (VS-6766) + defactinib
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Orlando, Florida • New Orleans, Louisiana • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Nov 12, 2026, 5:22 AM EST
Terminated Phase 2 Interventional Results available

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

NCT04720417
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Nov 12, 2026, 5:22 AM EST
Active, not recruiting Phase 2 Interventional Results available

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

NCT04439331
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Defactinib Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

NCT04625270
View directory record Official record
Conditions
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Interventions
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Scottsdale, Arizona • Santa Barbara, California • New Haven, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Nov 12, 2026, 5:22 AM EST
Recruiting Phase 3 Interventional

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781
View directory record Official record
Conditions
Low Grade Serous Ovarian Cancer
Interventions
avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Withdrawn Phase 1 Interventional

Pembrolizumab + Defactinib In Pleural Mesothelioma

NCT04201145
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Pembrolizumab, Defactinib
Drug
Lead sponsor
Raphael Bueno, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 12, 2026, 5:22 AM EST
Recruiting Phase 2 Interventional

Avutometinib and Defactinib in Diffuse Gastric Cancer

NCT06487221
View directory record Official record
Conditions
Gastric Cancer, Stomach Cancer
Interventions
Avutometinib, Defactinib
Drug
Lead sponsor
Ryan H. Moy, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2026 · Synced Nov 12, 2026, 5:22 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

NCT05787561
View directory record Official record
Conditions
Mesonephric Gynecologic Cancer
Interventions
Avutometinib (VS-6766), Defactinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 12, 2026, 5:22 AM EST